|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,110,000 |
Market
Cap: |
3.38(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$31.73 - $53.69 |
|
Level
I Sector: |
Consumer Discretionary |
Level
II Sector: |
Leisure |
Level
III Sector: |
Restaurants |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
|
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
24,200 |
99,487 |
198,726 |
249,694 |
Total Sell Value |
$1,216,805 |
$4,824,734 |
$8,206,765 |
$10,494,293 |
Total People Sold |
3 |
8 |
9 |
12 |
Total Sell Transactions |
4 |
12 |
20 |
35 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Harris Erik |
EVP & Chief Commercial Officer |
|
2021-03-01 |
4 |
AS |
$138.17 |
$341,280 |
D/D |
(2,470) |
28,520 |
|
-36% |
|
Harris Erik |
EVP & Chief Commercial Officer |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,136 |
30,990 |
|
- |
|
Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
|
2021-03-01 |
4 |
S |
$138.18 |
$587,956 |
D/D |
(4,255) |
40,761 |
|
36% |
|
Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,136 |
44,835 |
|
- |
|
Pinion John Richard |
See Remarks |
|
2021-03-01 |
4 |
S |
$138.17 |
$856,378 |
D/D |
(6,198) |
50,237 |
|
36% |
|
Pinion John Richard |
See Remarks |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,136 |
56,435 |
|
- |
|
Aliski William |
Director |
|
2021-02-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
64,704 |
|
- |
|
Aliski William |
Director |
|
2021-02-19 |
4 |
S |
$149.01 |
$1,117,575 |
D/D |
(7,500) |
65,704 |
|
36% |
|
Aliski William |
Director |
|
2021-02-19 |
4 |
OE |
$97.85 |
$733,875 |
D/D |
7,500 |
73,204 |
|
- |
|
Bedrosian Camille L |
EVP and Chief Medical Officer |
|
2021-01-30 |
4 |
S |
$140.36 |
$314,827 |
D/D |
(2,243) |
33,546 |
|
30% |
|
Bedrosian Camille L |
EVP and Chief Medical Officer |
|
2021-01-15 |
4 |
AS |
$139.18 |
$3,479,500 |
D/D |
(25,000) |
35,789 |
|
-25% |
|
Bedrosian Camille L |
EVP and Chief Medical Officer |
|
2021-01-15 |
4 |
OE |
$55.00 |
$1,375,000 |
D/D |
25,000 |
60,789 |
|
- |
|
Huizenga Theodore Alan |
SVP, Controller and PAO |
|
2021-01-07 |
4 |
AS |
$140.65 |
$562,600 |
D/D |
(4,000) |
15,716 |
|
-23% |
|
Huizenga Theodore Alan |
SVP, Controller and PAO |
|
2021-01-07 |
4 |
OE |
$21.00 |
$84,000 |
D/D |
4,000 |
20,436 |
|
- |
|
Kakkis Emil D |
President & CEO |
|
2021-01-04 |
4 |
AS |
$136.90 |
$4,107,000 |
I/I |
(30,000) |
2,329,741 |
|
-22% |
|
Kakkis Emil D |
President & CEO |
|
2020-11-02 |
4 |
AS |
$96.82 |
$2,904,600 |
I/I |
(30,000) |
2,359,741 |
|
35% |
|
Parschauer Karah Herdman |
EVP and General Counsel |
|
2020-10-30 |
4 |
AS |
$100.12 |
$991,488 |
D/D |
(9,903) |
24,061 |
|
26% |
|
Parschauer Karah Herdman |
EVP and General Counsel |
|
2020-10-30 |
4 |
OE |
$54.50 |
$539,714 |
D/D |
9,903 |
33,871 |
|
- |
|
Parschauer Karah Herdman |
EVP and General Counsel |
|
2020-10-28 |
4 |
AS |
$100.00 |
$9,700 |
D/D |
(97) |
23,968 |
|
26% |
|
Parschauer Karah Herdman |
EVP and General Counsel |
|
2020-10-28 |
4 |
OE |
$54.50 |
$5,287 |
D/D |
97 |
24,065 |
|
- |
|
Harris Erik |
EVP & Chief Commercial Officer |
|
2020-10-14 |
4 |
S |
$88.00 |
$19,360 |
D/D |
(220) |
23,370 |
|
-54% |
|
Huizenga Theodore Alan |
SVP, Controller and PAO |
|
2020-10-14 |
4 |
S |
$87.98 |
$12,845 |
D/D |
(146) |
16,436 |
|
-54% |
|
Pinion John Richard |
See Remarks |
|
2020-10-14 |
4 |
S |
$88.00 |
$23,056 |
D/D |
(262) |
46,299 |
|
-54% |
|
Kakkis Emil D |
President & CEO |
|
2020-10-14 |
4 |
D |
$92.69 |
$78,972 |
D/D |
(852) |
610,189 |
|
- |
|
Bedrosian Camille L |
EVP and Chief Medical Officer |
|
2020-10-14 |
4 |
S |
$88.00 |
$23,056 |
D/D |
(262) |
35,789 |
|
-54% |
|
628 Records found
|
|
Page 8 of 26 |
|
|